Harnessing Allostery: A Novel Approach to Drug Discovery

Medicinal Research Reviews

Volumn 34, Issue 6, 2014, Pages 1242-1285

  Lu, Shaoyong ^a   Li, Shuai ^a   Zhang, Jian ^a,b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Allosteric modulators; Allosteric proteins; Allosteric sites; Allostery; Drug discovery

Indexed keywords

ABELSON KINASE; ALANINE; CASEIN KINASE II; CYCLIN DEPENDENT KINASE 2; FLUORESCENT DYE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NEW DRUG; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE; PROTEIN; PROTEIN BINDING;

ALLOSTERISM; ARTICLE; BINDING SITE; CHEMICAL MODEL; CHEMICAL STRUCTURE; DRUG DEVELOPMENT; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; MACROMOLECULE; MUTAGENESIS; PHOTOAFFINITY LABELING; SIGNAL TRANSDUCTION; SIMULATION; VIRTUAL REALITY; METABOLISM; PROCEDURES; SENSITIVITY AND SPECIFICITY;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; BINDING SITES; DRUG DISCOVERY; HUMANS; PROTEIN BINDING; PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 84907979005     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21317     Document Type: Article

References (216)

1. Eisenberg D, Marcotte EM, Xenarios I, Yeates TO. Protein function in the post-genomic era. Nature 2000;405:823-826.
2. Changeux J-P. Allosteric receptors: From electric organ to cognition. Annu Rev Pharmacol Toxicol 2010;50:1-38.
3. Changeux J-P. The concept of allosteric modulation: An overview. Drug Discov Today 2013;10:e223-e228.
4. Bu Z, Callaway DJ. Proteins move! Protein dynamics and long-range allostery in cell signaling. Adv Protein Chem Struct Biol 2011;83:163-221.
5. Maksay G. Allostery in pharmacology: Thermodynamics, evolution and design. Prog Biophys Mol Biol 2011;106:463-473.
6. Kar G, Keskin O, Gursoy A, Nussinov R. Allostery and population shift in drug discovery. Curr Opin Pharmacol 2010;10:715-722.
7. Peracchi A, Mozzarelli A. Exploring and exploiting allostery: Models, evolution, and drug targeting. Biochim Biophys Acta 2011;1814:922-933.
8. Csermely P, Palotai R, Nussinov R. Induced fit, conformational selection and independent dynamics segments: An extended view of binding events. Trends Biochem Sci 2010;35:539-546.
9. Cui Q, Karplus M. Allostery and cooperativity revisited. Protein Sci 2008;17:1295-1307.
10. Pan YP, Tsai C-J, Ma B, Nussinov R. Mechanism of transcription factor selectivity. Trends Genet 2010;26:75-83.
11. Sinha N, Nussinov R. Point mutations and sequence variability in proteins: Redistributions of preexisting populations. Proc Natl Acad Sci USA 2001;98:3130-3144.
12. Kalodimos CG. Protein function and allostery: A dynamic relationship. Ann N Y Acad Sci 2012;1260:81-86.
13. Changeux J-P, Edelstein SJ. Allosteric mechanism of signal transduction. Science 2005;308:1424-1428.
14. del Sol A, Tsai C-J, Ma B, Nussinov R. The original of allosteric functional modulation: Multiple pre-existing pathways. Structure 2009;17:1042-1050.
15. Shi Z, Resing KA, Ahn NG. Networks for the allosteric control of protein kinases. Curr Opin Struct Biol 2006;16:686-692.
16. Laine E, de Beauchene IC, Perahia D, Auclair C, Tchertanov L. Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: Implications for dimerization and activation mechanisms. PLoS Comput Biol 2011;7:e1002068.
17. Dixit A, Verkhivker GM. Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases. PLoS Comput Biol 2011;7:e1002179.
18. Chiappori F, Merelli I, Colombo G, Milanesi L, Morra G. Molecular mechanism of allosteric communication in Hsp70 revealed by molecular dynamics simulations. PLoS Comput Biol 2012;8:e1002844.
19. Nussinov R, Ma B, Tsai C-J, Csermely P. Allosteric conformational barcodes direct signaling in the cell. Structure 2013;21:1509-1521.
20. Huang M, Lu S, Shi T, Zhao Y, Chen Y, Li X, Liu X, Huang Z, Zhang J. Conformational transition pathway in the activation process of allosteric glucokinase. PLOS ONE 2013;8:e55857.
21. Goodey NM, Benkovic SJ. Allosteric regulation and catalysis emerge via a common route. Nat Chem Biol 2008;4:474-482.
22. Nussinov R, Tsai C-J. Allostery in disease and in drug discovery. Cell 2013;153:293-305.
23. Nussinov R, Tsai C-J, Xin F, Radivojac P. Allosteric post-translational modification codes. Trends Biochem Sci 2012;37:447-455.
24. Hardy JA, Wells JA. Searching for new allosteric sites in enzymes. Curr Opin Struct Biol 2004;14:706-715.
25. Tzeng S-R, Kalodimos CG. Protein dynamics and allostery: An NMR view. Curr Opin Struct Biol 2011;21:62-27.
26. Prasannan CB, Villar MT, Artigues A Fenton AW. Identification of regions of rabbit muscle pyruvate kinase important for allosteric regulation by phenylalanine, detected by H/D exchange mass spectrometry. Biochemistry 2013;52:1998-2006.
27. Wu S, Vysotskaya ZV, Xu X, Xie C, Liu Q, Zhou L. State-dependent cAMP binding to functioning HCN channels studied by patch-clamp fluorometry. Biophys J 2011;100:1226-1232.
28. Wang X, Horswill JG, Whalley BJ, Stephens GJ. Effects of the allosteric antagonist 1-(4-Chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum. Mol Pharmacol 2011;79:758-767.
29. Zhang J, Li C, Chen K, Zhu W, Shen X, Jiang H. Conformational transition pathway in the allosteric process of human glucokinase. Proc Natl Acad Sci USA 2006;103:13368-13373.
30. Liu J, Nussinov R. Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design. Proc Natl Acad Sci USA 2008;108:901-906.
31. Sahun-Roncero M, Rubio-Ruiz B, Saladino G, Conejo-Garcia A. The mechanism of allosteric coupling in choline kinase α1 revealed by the action of a rationally designed inhibitor. Angew Chem Int Ed 2013;52:4582-4586.
32. Lu S, Jiang Y, Lv J, Zou J, Wu T. Mechanism of kinase inactivation and nonbinding of FRATide to GSK3β due to K85M mutation: Molecular dynamics simulation and normal mode analysis. Biopolymers 2011;95:669-681.
33. Chennubhotla C, Bahar I. Markov propagation of allosteric effects in biomolecular systems: Application to GroEL-GroES. Mol Syst Biol 2006;2:1-13.
34. De Ruvo M, Giuliani A, Paci P, Santoni D, Di Paola L. Shedding light on protein-ligand binding by graph theory: The topological nature of allostery. Biophys Chem 2012;165-166:21-29.
35. Kaya C, Armutlulu A, Ekesan S, Haliloglu T. MCPath: Monte Carlo path generation approach to predict likely allosteric pathways and functional residues. Nucleic Acids Res 2013;41:W249-W255.
36. Huang Z, Mou L, Shen Q, Lu S, Li C, Liu X, Wang G, Li S, Geng L, Chen G, Zhang J. ASD v2.0: Updated content and novel features focusing on allosteric regulation. Nucleic Acids Res 2014;42:D510-D516.
37. Nussinov R, Tsai C-J. The different ways through which specificity works in orthosteric and allosteric drugs. Curr Pharm Des 2012;18:1311-1316.
38. Fang Z, Grutter C, Rauh D. Strategies for the selective regulation of kinases with allosteric modulators: Exploring exclusive structural features. ACS Chem Biol 2012;8:58-70.
39. Wootten D, Christopoulos A, Sexton PM. Emerging paradigms in GPCR allostery: Implications for drug discovery. Nat Rev Drug Discov 2013;12:630-644.
40. Palmieri L, Rastelli G. αC helix displacement as a general approach for allosteric modulation of protein kinases. Drug Discov Today 2012;18:407-414.
41. Lamba V, Ghosh I. New directions in targeting protein kinases: Focusing upon true allosteric and bivalent inhibitors. Curr Pharm Des 2012;18:2936-2945.
42. Taly A, Corringer PJ, Guedin D, Lestage P, Changeux J-P. Nicotinic receptors: Allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 2009;8:733-750.
43. Christopoulos A. Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery. Nat Rev Drug Discov 2002;1:198-210.
44. Quoyer J, Janz JM, Luo J, Ren Y, Armando S, Lukashova V, Benovic JL, Carlson KE, Hunt III SW, Bouvier M. Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci USA 2013;110:E5088-E5097.
45. Wilhelm A, Lopez-Garcia LA, Busschots K, Frohner W, Maurer F, Boettcher S, Zhang H, Schulze JO, Biondi RM, Engel M. 2-(3-Oxo-1, 3-diphenylpropyl)malonic acids as potent allosteric ligands of the PIF pocket of phosphoinositide-dependent kinase-1: Development and prodrug concept. J Med Chem 2012;55:9817-9830.
46. Monod J, Changeux J-P, Jacob J. Allosteric proteins and cellular systems. J Mol Biol 1963;6:306-329.
47. Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 2004;12:429-438.
48. Lee J, Natarajan M, Nashine VC, Socolich M, Vo T, Russ WP, Benkovic SJ, Ranganathan R. Surface sites for engineering allosteric control in proteins. Science 2008;322:438-442.
49. Villaverde A. Allosteric enzymes as biosensors for molecular diagnosis. FEBS Lett 2003;554:169-172.
50. Monod J, Wyman J, Changeux J-P. On the nature of allosteric transitions: A plausible model. J Mol Biol 1965;12:88-118.
51. Changeux J-P. 50 Years of allosteric interactions: The twists and turns of the models. Nat Rev Drug Discov 2013;14:1-11.
52. Changeux J-P. Allostery and the Monod-Wyman-Changeux model after 50 years. Ann Rev Biophys 2012;41:103-133.
53. Horovitz A, Willison KR. Allosteric regulation of chaperonins. Curr Opin Struct Biol 2005;15:646-651.
54. Horwich AL, Fenton WA, Chapman E, Farr GW. Two families of chaperonin: Physiology and mechanism. Annu Rev Cell Dev Biol 2007;23:115-145.
55. Shimizu TS, Le Novere N, Levin MD, Beavil AJ, Sutton BJ, Bray D. Molecular model of a lattice of signaling proteins involved in bacterial chemotaxis. Nat Cell Biol 2000;2:792-796.
56. Eaton WA, Henry ER, Hofrichter J, Bettati S, Viappiani C, Mozzarelli A. Evolution of allosteric models for hemoglobin. IUBMB Life 2007;59:586-599.
57. Henry ER, Bettati S, Hofrichter J, Eaton W. A tertiary two-state allosteric model for hemoglobin. Biophys Chem 2002;98:149-164.
58. Viappiani C, Bettati S, Bruno S, Ronda L, Abbruzzetti S, Mozzarelli A, Eaton WA. New insights into allosteric mechanisms from trapping unstable protein conformations in silica gels. Proc Natl Acad Sci USA 2004;101:14414-14419.
59. Koshland DE, Nemethy G, Filmer D. Comparison of experimental binding data and theoretical model in proteins containing subunits. Biochemistry 1966;5:365-385.
60. Boehr DD, Nussinov R, Wright PE. The role of dynamic conformational ensembles in biomolecular recognition. Nat Chem Biol 2009;5:789-796.
61. Tzeng S-R, Kalodimos CG. Allosteric inhibition through suppression of transient conformational states. Nat Chem Biol 2013;9:462-465.
62. Nussinov R, Ma B, Tsai C-J. A broad view of scaffolding suggests that scaffolding proteins can actively control regulation and signaling of multienzyme complexes through allostery. Biochim Biophys Acta 2013;1834:820-829.
63. Jaffe EK. Morpheeins-A new structural paradigm for allosteric regulation. Trends Biochem Sci 2005;30:490-497.
64. Selwood T, Jaffe EK. Dynamic dissociating homo-oligomers and the control of protein function. Arch Biochem Biophys 2012;519:131-143.
65. Jaffe EK. Impact of quaternary structural dynamics on allosteric drug discovery. Curr Top Med Chem 2013;13:55-63.
66. Jaffe EK, Lawrence SH. The Morpheein model of allostery: Evaluating proteins as potential Morpheeins. Methods Mol Biol 2012;796:217-231.
67. Tzeng S-R, Kalodimos CG. Dynamics activation of an allosteric regulatory protein. Nature 2009;462:368-372.
68. Tzeng S-R, Kalodimos CG. Protein activity regulation by conformational entropy. Nature 2012;488:236-240.
69. Tsai C-J, de Sol A, Nussinov R. Allostery: Absence of a change in shape does not imply that allostery is not at play. J Mol Biol 2008;378:1-11.
70. Huang Z, Zhu L, Cao Y, Wu G, Liu X, Chen Y, Wang Q, Shi T, Zhao Y, Wang Y, Li W, Li Y, Chen H, Chen G, Zhang J. ASD: A comprehensive database of allosteric proteins and modulators. Nucleic Acids Res 2011;39:D663-D669.
71. Li X, Chen Y, Lu S, Huang Z, Liu X, Wang Q, Shi T, Zhang J. Toward an understanding of the sequence and structural basis of allosteric proteins. J Mol Graph Model 2013;40:30-39.
72. Namboodiri S, Giuliani A, Nair AS, Dhar PK. Looking for a sequence based allostery definition: A statistical journey at different resolution scales. J Theor Biol 2012;304:211-218.
73. Yang JS, Seo SW, Jang S, Jung GY, Kim S. Rational engineering of enzyme allosteric regulation through sequence evolution analysis. PLoS Comput Biol 2012;8:e1002612.
74. Lane JR, Abdul-Ridha A, Canals M. Regulation of G protein-coupled receptors by allosteric ligands. ACS Chem Neurosci 2013;4:527-534.
75. Wang CI, Lewis RJ. Emerging opportunities for allosteric modulation of G-protein coupled receptors. Biochem Pharmacol 2013;85:153-162.
76. Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA. Allosteric modulators for the treatment of schizophrenia: Targeting glutamatergic networks. Curr Top Med Chem 2013;13:26-54.
77. Nickols HH, Conn PJ. Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol Dis 2014;61:55-71.
78. Muller CE, Schiedel AC, Baqi Y. Allosteric modulators of rhodopsin-like G protein-coupled receptors: Opportunities in drug development. Pharmacol Ther 2012;135:292-315.
79. Preininger AM, Meiler J, Hamm HE. Conformational flexibility and structural dynamics in GPCR-mediated G protein activation: A perspective. J Mol Biol 2013;425:2288-2298.
80. Lu S-Y, Jiang Y-J, Lv J, Wu T-X, Yu Q-S, Zhu W-L. Molecular docking and molecular dynamics simulation studies of GPR40 receptor-agonist interactions. J Mol Graph Model 2010;28:766-774.
81. Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, Li T, Ma L, Fenalti G, Li J, Zhang W, Xie X, Yang H, Jiang H, Cherezov V, Liu H, Stevens RC, Zhao Q, Wu B. Structure of the CCR5 chemokine receptor-HIV entry inhibitor Maraviroc complex. Science 2013;341:1387-1390.
82. Bock A, Merten N, Schrage R, Dallanoce C, Batz J, Klockner J, Schmitz J, Matera C, Simon K, Kebig A, Peters L, Muller A, Schrobang-Ley J, Trankle C, Hoffmann C, De Amici M, Holzgrabe U, Kostenis E, Mohr K. The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling. Nat Commun 2012;3:1044.
83. Arias HR. Positive and negative modulation of nicotinic receptors. Adv Protein Chem Struct Biol 2010;80:153-203.
84. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009;8:41-54.
85. Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 2008;117:232-243.
86. Valant C, Felder CC, Sexton PM, Christopoulos A. Probe dependence in the allosteric modulation of a G protein-coupled receptor: Implications for diction and validation of allosteric ligand effects. Mol Pharmacol 2012;81:41-52.
87. Willard FS, Wootten D, Showalter AD, Savage EE, Ficorilli J, Farb TB, Bokvist K, Alsina-Fernandez J, Furness SGB, Christopoulos A, Sexton PM, Sloop KW. Small molecule allosteric modulation of the glucagon-like peptide 1 receptor enhances the insulinotropic effect of oxytomodulin. Mol Pharmacol 2012;82:1066-1073.
88. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, Miller LJ, Summers RJ, Christopoulos A, Sexton PM. Allosteric ligands of the glucagons-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: Implications for drug screening. Mol Pharmacol 2010;78:456-465.
89. 4 receptor positive allosteric modulation and concomitant activation of Gq coupled receptors. Neuropharmacology 2013;66:122-132.
90. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-621.
91. Tao YX. The melanocortin-4 receptor: Physiology, pharmacology, and pathophysiology. Endocr Rev 2010;31:506-543.
92. Gardella TJ, Juppner H. Interaction of PTH and PTHrP with their receptors. Rev Endocr Metab Disord 2000;1:317-329.
93. Halls ML, van der Westhuizen ET, Bathgate RA, Summers RJ. Relaxin family peptide receptors-Former orphans reunite with their parent ligands to activate multiple signaling pathways. Br J Pharmacol 2007;150:677-691.
94. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM. International union of pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002;54:233-246.
95. Leach K, Sexton PM, Christtopoulos A. Allosteric GPCR modulators: Taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 2007;28:382-389.
96. Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 2010;62:265-304.
97. Gao Z-G, Jacobson KA. Allosteric modulation and functional selectivity of G protein-coupled receptors. Drug Discov Today 2013;10:e237-e243.
98. Goupil E, Laporte SA, Hebert TE. Functional selectivity in GPCR signaling: Understanding the full spectrum of receptor conformations. Mini Rev Med Chem 2012;12:817-830.
99. Seifert R. Functional selectivity of G protein-coupled receptors: From recombinant systems to native human cells. Biochem Pharmacol 2013;86:853-861.
100. Wacker D, Wang C, Katritch V, Han GW, Huang X-P, Vardy E, McCorvy JD, Jiang Y, Chu M, Siu FY, Liu W, Xu HE, Cherezov V, Roth BL, Stevens RC. Structural features for functional selectivity at serotonin receptors. Science 2013;340:615-619.
101. Quoyer J, Janz JM, Luo J, Ren Y, Armando S, Lukashova V, Benovic JL, Carlson KE, Hunt SW, III, Bouvier M. Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad USA 2013;110:5088-5097.
102. 1 muscarinic acetylcholine receptor orthosteric and allosteric agonists. J Pharmacol Exp Ther 2008;327:365-374.
103. 1 receptor. J Med Chem 2012;55:2367-2375.
104. Narlike-Grassow M, Blanco-Aparicio C, Carnero A. The PIM family of serine/threonine kinases in cancer. Med Res Rev 2014;34:136-159.
105. Meharena HS, Chang P, Keshwani MK, Oruganty K, Nene AK, Kannan N, Taylor SS, Kornev AP. Deciphering the structural basis of eukaryotic protein kinase regulation. PLOS Biol 2013;11:e1001680.
106. Lu S-Y, Jiang Y-J, Zou J-W, Wu T-X. Molecular modeling and molecular dynamics simulation studies of the GSK3β/ATP/substrate complex: Understanding the unique P+4 primed phosphorylation specificity for GSK3β substrates. J Chem Inf Model 2011;51:1025-1036.
107. Lu S-Y, Huang Z-M, Huang W-K, Liu X-Y, Chen Y-Y, Shi T, Zhang J. How calcium inhibits the magnesium-dependent kinase GSK3β: A molecular simulation study. Proteins 2013;81:740-753.
108. Lu S-Y, Jiang Y-J, Zou J-W, Wu T-X. Effect of double mutations K214/A-E215Q of FRATide on GSK3β: Insights from molecular dynamics simulation and normal mode analysis. Amino Acids 2012;43:267-277.
109. EI-Gamal M, Anbar HS, Yoo KH, Oh C-H. FMS kinase inhibitors: Current status and future prospects. Med Res Rev 2013;33:599-636.
110. Manetti F. LIM kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Med Res Rev 2012;32:968-998.
111. Lu S-Y, Jiang Y-J, Lv J, Zou J-W, Wu T-X. Role of bridging water molecules in GSK3β-inhibitor complexes: Insights from QM/MM, MD, and molecular docking studies. J Comput Chem 2011;32:1907-1918.
112. Calleja V, Laguerre M, Parker PJ, Larijani B. Role of a novel PH-kinase domain interface in PKB/Akt regulation: Structural mechanism for allosetric inhibition. PLoS Biol 2009;7:e1000017.
113. Wu W-I, Voegtli WC, Sturgis HL, Dizon FP, Vigers GPA, Brandhuber BJ. Crystal structure of human Akt1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS ONE 2011;5:e12913.
114. Ashwell MA, Lapierre J-M, Brassard C, Bresciano K, Bull C, Cornell-Kennon S, Eathiraj S, France DS, Hall T, Hill J, Kelleher E, Khanapurkar S, Kizer D, Koerner S, Link J, Liu Y, Makhija S, Moussa M, Namdev N, Nguyen K, Nicewonger R, Palma R, Szwaya J, Tandon M, Uppalapati U, Vensel D, Volak LP, Volckova E, Westlund N, Wu H, Yang R-Y, Chan TCK. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4, 5-b]pyridine-2-yl)pyridine-2-amines: Orally bioavailable, selective, and potent ATP-independent Akt inhibitors. J Med Chem 2012;55:5291-5310.
115. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 2010;11:9-22.
116. Hindie V, Stroba A, Zhang H, Lopez-Garcia LA, Idrissova L, Zeuzem S, Hirschberg D, Schaeffer F, Jorgensen TJD, Engel M, Alzari PM, Biondi RM. Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. Nat Chem Biol 2009;5:758-764.
117. Pluk H, Dorey K, Superti-Furga G. Autoinhibition of c-Abl. Cell 2002;108:247-259.
118. Skora L, Mestan J, Fabbro D, Jahnke W, Grzesiek S. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors. Proc Natl Acad Sci USA 2013;110:4437-4445.
119. O'Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242-2249.
120. Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, Sim T, Powers J, Dierks C, Sun F, Guo G-R, Ding Q, Okram B, Choi Y, Wojciechowski A, Deng X, Liu G, Fendrich G, Strauss A, Vajpai N, Grzesiek S, Tuntland T, Liu Y, Bursulaya B, Azam M, Manley PW, Engen JR, Daley GQ, Warmuth M, Gray NS. Targeting Bcr-Abl by combing allosteric with ATP-binding-site inhibitors. Nature 2010;463:501-507.
121. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011;11:558-572.
122. Betzi S, Alam R, Martin M, Lubbers DJ, Han H, Jakkaraj SR, Georg GI, Schonbrunn E. Discovery of potential allosteric ligand binding site in CDK2. ACS Chem Biol 2011;6:492-501.
123. Cozza G, Pinna LA, Moro S. Kinase CK2 inhibition: An update. Curr Med Chem 2013;20:671-693.
124. Raaf J, Brunstein E, Issinger O-G, Niefind K. The CK2α/CK2β interface of human protein kinase CK2 harbors a binding pocket for small molecules. Chem Biol 2008;15:111-117.
125. Rusconi P, Caiola E, Broggini M. RAS/RAF/MEK inhibitors in oncology. Curr Med Chem 2012;19:1164-1176.
126. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McMonnell P, Spessard C, Banotai C, Mueller WT, Delaney A, Omer C, Sebolt-Leopold J, Dudley DT, Leung IK, Flamme C, Warmus J, Kaufman M, Barrett S, Tecle H, Hasemann CA. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004;11:1192-1197.
127. Buttner A, Cottin T, Xu J, Tzaqkaroulaki L, Giannis A. Serotonin derivatives as a new class of non-ATP-competitive receptor tyrosine kinase inhibitors. Bioorg Med Chem 2010;18:3387-3402.
128. Blum G, Gazit A, Levitzki A. Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J Biol Chem 2003;278:40442-40454.
129. Manley PW, Bold G, Bruggen J, Fendrich G, Furet P, Mestan J, Schnell C, Stolz B, Meyer T, Meyhack B, Stark W, Strauss A, Wood J. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim Biophys Acta 2004;1697:17-27.
130. Xiao B, Sanders MJ, Carmena D, Bright NJ, Haire LF, Underwood E, Patel BP, Heath RB, Walker PA, Hallen S, Giordanetto F, Martin SR, Carling D, Gamblin SJ. Structural basis of AMPK regulation by small molecule activators. Nat Commun 2013;4:3017.
131. Marinho-Carvalho MM, Costa-Mattos PV, Spitz GA, Zancan P, Sola-Penna M. Calmodulin upregulates skeletal muscle 6-phorphofructo-1-kinase reversing the inhibitory effects of allosetric modulators. Biochim Biophys Acta 2009;1794:1175-1180.
132. Takahashi K, Hashimoto N, Nakama C, Kamata K, Sasaki K, Yoshimoto R, Ohyama S, Hosaka H, Maruki H, Nagata Y, Eiki J, Nishimura T. The design and optimization of a series of 2-(pyridine-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators. Bioorg Med Chem 2009;17:7042-7051.
133. Butini S, Gemma S, Brindisi M, Borrelli G, Lossani A, Ponte AM, Torti A, Maga G, Marinelli L, La Pietra V, Fiorini I, Lamponi S, Campiani G, Zisterer DM, Nathwani SM, Sartini S, La Motta C, Da Settimo F, Novellino E, Focher F. Non-nucleoside inhibitors of human adenosine kinase: Synthesis, molecular modeling, and biological studies. J Med Chem 2011;54:1401-1420.
134. Montalban AG, Boman E, Chang CD, Ceide SC, Dahl R, Dalesandro D, Delaet NG, Erb E, Ernst JT, Gibbs A, Kahl J, Kessler L, Lundstrom J, Miller S, Nakanishi H, Roberts E, Saiah E, Sullivan R, Wang Z, Larson CJ. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors. Bioorg Med Chem Lett 2008;18:1772-1777.
135. Converso A, Hartingh T, Garbaccio RM, Tasber E, Rickert K, Fraley ME, Yan Y, Kreatsoulas C, Stirdivants S, Drakas B, Walsh ES, Hamilton K, Buser CA, Mao X, Abrams MT, Beck SC, Tao W, Lobell R, Sepp-Lorenzino L, Zugay-Murphy J, Sardana V, Munshi SK, Jezequel-Sur SM, Zuck PD, Hartman GD. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg Med Chem Lett 2009;19:1240-1244.
136. Frohner W, Lopez-Garcia LA, Neimanis S, Weber N, Navratil J, Maurer F, Stroba A, Zhang H, Biondi RM, Engel M. 4-Benzimidazolyl-3-phenylbutanoic acids as novel PIF-pocket-targeting allosteric inhibitors of protein kinase PKCξ. J Med Chem 2011;54:6714-6723.
137. Christian F, Szaszak M, Friedl S, Drewianka S, Lorenz D, Goncalves A, Furkert J, Vargas C, Schmieder P, Gotz F, Zuhlke K, Moutty M, Gottert H, Joshi M, Reif B, Haase H, Morano I, Grossmann S, Klukovits A, Gaspar R, Noack C, Berqmann M, Kass R, Hampel K, Kashin D, Genieser HG, Herberg FW, Willoughby D, Cooper DM, Baillie GS, Houslay MD, von Kries JP, Zimmermann B, Rosenthal W, Klussmann E. Small molecule AKAP-protein kinase A (PKA) interaction disrupts that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. J Biol Chem 2011;286:9079-9096.
138. Aledo JC, Gomez-Fabre PM, Olalla L, Marquez J. Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mamm Genome 2000;11:1107-1110.
139. DeLaBarre B, Gross S, Fang C, Gao Y, Jha A, Jiang F, Song JJ, Wei W, Hurov JB. Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry 2011;50:10764-10770.
140. Thangavelu K, Pan CQ, Karlberg T, Balaji G, Uttamchandani M, Suresh V, Schuler H, Low BC, Sivaraman J. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc Natl Acad Sci USA 2012;109:7705-7710.
141. Shukla K, Ferraris DV, Thomas AG, Stathis M, Duvall B, Delahanty G, Alt J, Rais R, Rojas C, Gao P, Xiang Y, Dang CV, Slusher BS, Tsukamoto T. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem 2012;55:10551-10563.
142. Conti P, Tamborini L, Pinto A, Blondel A, Minoprio P, Mozzarelli A, De Micheli C. Drug discovery targeting amino acid racemases. Chem Rev 2011;111:6919-6946.
143. Campanini B, Spyrakis F, Peracchi A, Mozzarelli A. Serine racemase: A key player in neuron activity and in neuropathologies. Front Biosci 2013;18:1112-1128.
144. Wolosker H. NMDA receptor regulation by d-serine: New findings and perspectives. Mol Neurobiol 2007;36:152-164.
145. Marchetti M, Bruno S, Campanini B, Peracchi A, Mai N, Mozzarelli A. ATP binding to human serine recemase is cooperative and modulated by glycine. FEBS J 2013;280:5853-5863.
146. Mohr K, Schmitz J, Schrage R, Trankle C, Holzgrabe U. Molecular alliance from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors. Angew Chem Int Ed 2013;52:508-516.
147. Daval SB, Kellenberger E, Bonnet D, Utard V, Galzi J-L, Llien B. Exploration of the orthosteric/allosteric interface in human M1 muscarinic receptors by bitopic fluorescent ligand. Mol Pharmacol 2013;84:71-85.
148. Nussinov R, Tsai C-J, Ma B. The underappreciated role of allostery in the cellular network. Annu Rev Biophys 2013;42:169-189.
149. Nussinov R. The spatial structure of cell signaling systems. Phys Biol 2013;10:045004.
150. Nussinov R, Tsai C-J, Csermely P. Allo-network drugs: Harnessing allostery in cellular networks. Trends Biochem Sci 2011;32:686-693.
151. Szilagyi A, Nussinov R, Csermely P. Allo-network drugs: Extension of the allosteric drug concept to protein-protein interaction and signaling networks. Curr Top Med Chem 2013;13:64-77.
152. Csermely P, Nussinov R, Szilagyi A. From allosteric drugs to allo-network drugs: State of the art and trends of design, synthesis, and computational methods. Curr Top Med Chem 2013;13:2-4.
153. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: Lessons from mTOR inhibitors. Biochim Biophys Acta 2010;1804:433-439.
154. Efeyan A, Sabatini DM. mTOR and cancer: Many loops in one pathway. Curr Opin Cell Biol 2012;22:169-176.
155. Wang Q, Zheng M, Huang Z, Liu X, Zhou H, Chen Y, Shi T, Zhang J. Toward understanding the molecular basis for chemical allosteric modulator design. J Mol Graph Model 2012;38:324-333.
156. Sadowsky JD, Burlingame MA, Wolan DW, McClendon CL, Jacobson MP, Wells JA. Turning a protein kinase on or off from a single allosteric site via disfulfide trapping. Proc Natl Acad Sci USA 2011;108:6056-6061.
157. Scheer JM, Romanowski MJ, Wells JA. A common allosteric site and mechanism in caspases. Proc Natl Acad Sci USA 2006;103:7595-7600.
158. Erlanson DA, Wells JA, Braisted AC. Tethering: Fragment-based drug discovery. Annu Rev Biophys Biomol Struct 2004;33:199-223.
159. Slebos RJC. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323:561-565.
160. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013;503:548-551.
161. Hacker HG, Sisay MT, Gutschow M. Allosteric modulation of caspases. Pharmacol Ther 2011;132:180-195.
162. Gao J, Wells JA. Identification of specific tethered inhibitors for caspase-5. Chem Biol Drug Des 2012;79:209-215.
163. Modesti M. Fluorescent labeling of proteins. Methods Mol Biol 2011;783:101-120.
164. Simard JR, Kluter S, Grutter C, Getlik M, Rabiller M, Rode HB, Rauth D. A new screening assay for allosteric inhibitors of cSrc. Nat Chem Biol 2009;5:394-396.
165. Link H, Kochanowski K, Sauer U. Systematic identification of allosteric protein-metabolite interactions that control enzyme activity in vivo. Nat Biotechnol 2013;31:357-362.
166. Lu S-Y, Jiang Y-J, Zou J-W, Wu T-X. Dissection of the difference between the group I metal ions in inhibiting GSK3β: A computational study. Phys Chem Chem Phys 2011;13:7014-7023.
167. Simard JR, Getlik M, Grutter C, Pawar V, Wulfert S, Rabiller M, Rauth D. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. J Am Chem Soc 2009;131:13286-13296.
168. Schneider R, Becker C, Simard JR, Cetlik M, Bohlke N, Janning P, Rauh D. Direct binding assay for the detection of type IV allosteric inhibitors of Abl. J Am Chem Soc 2012;134:9138-9141.
169. Lee S, Wang Q. Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B. Med Res Rev 2007;27:553-573.
170. Wiesmann C, Barr KJ, Kung J, Zhu J, Erlanson DA, Shen W, Fahr BJ, Zhong M, Taylor L, Randal M, McDowell RS, Hansen SK. Allosteric inhibition of protein tyrosine phosphatase 1B. Nat Struct Mol Biol 2004;8:730-737.
171. Schneider R, Beumer C, Simard JR, Grutter C, Rauh D. Selective detection of allosteric phosphatase inhibitors. J Am Chem Soc 2013;138:6838-6841.
172. Wenthur CJ, Gentry PR, Mathews TP, Lindsley CW. Drugs for allosteric sites on receptors. Annu Rev Pharmacol Toxicol 2014;54:9.1-9.20.
173. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, Green DVS, Hertzberg RP, Janzen WP, Paslay JW, Schopfer U, Sittampalam GS. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 2011;10:188-195.
174. Feldman T, Kabaleeswaran V, Jang SB, Antczak C, Djaballah H, Wu H, Jiang X. A class of allosteric caspase inhibitors identified by high-throughput screening. Mol Cell 2012;47:585-595.
175. Stokes MJ, Guther MLS, Turnock DC, Prescott AR, Martin KL, Alphey MS, Ferguson MAJ. The synthesis of UDP-N-acetylglucosmine is essential for bloodstream from Trypanosoma brucei in vitro and in vivo and UDP-N-acetylglucosamine starvation reveals a hierarchy in parasite protein glycoslyation. J Biol Chem 2008;283:16147-16161.
176. Urbaniak MD, Collie IT, Fang W, Aristotelous T, Eskilsson S, Raimi OG, Harrison J, Navratilova IH, Frearson JA, van Aalten DMF, Ferguson MAJ. A novel allosteric inhibitor of the uridine diphosphate N-acetylglucosamine pyrophosphorylase from Trypanosoma brucei. ACS Chem Biol 2013;8:1981-1987.
177. Bembenek SD, Tounge BA, Reynolds CH. Ligand efficiency and fragment-based drug discovery. Drug Discov Today 2009;14:278-283.
178. Hajduk PJ, Greer J. A decade of fragment-based drug design: Strategies advances and lessons learned. Nat Rev Drug Discov 2007;6:211-219.
179. Schulz MN, Hubbard RE. Recent progress in fragment-based lead discovery. Curr Opin Pharmacol 2009;9:615-621.
180. Chessari G, Woodhead AJ. From fragment to clinical candidate-A historical perspective. Drug Discov Today 2009;14:668-675.
181. Murray CW, Rees DC. The rise of fragment-based drug discovery. Nat Chem 2009;1:187-192.
182. Gozalbes R, Carbajo RJ, Pineda-Lucena A. Contributions of computational chemistry and biophysical techniques to fragment-based drug discovery. Curr Med Chem 2007;17:1769-1794.
183. Larsson A, Jansson A, Aberg A, Nordlund P. Efficiency of hit generation and structural characterization in fragment-based ligand discovery. Curr Opin Chem Biol 2011;15:482-488.
184. Scott DE, Coyne AG, Hudson SA, Abell C. Fragment-based approaches in drug discovery and chemical biology. Biochemistry 2012;51:4990-5003.
185. Sheng C, Zhang W. Fragment informatics and computational fragment-based drug design: An overview and update. Med Res Rev 2013;33:554-598.
186. Flaherty KT, Yasothan U, Kirkpatrick P, Vemurafenib. Nat Rev Drug Discov 2011;10:811-812.
187. Krimm I, Lancelin J-M, Praly J-P. Binding evaluation of fragment-based scaffolds for probing allosteric enzymes. J Med Chem 2012;55:1287-1295.
188. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-2658.
189. Simoni D, Gebbia N, Invidiata FP, Eleopra M, Marchetti P, Rondanin R, Baruchello R, Provera S, Marchioro C, Tolomeo M, Marinelli L, Limongelli V, Novellino E, Kwaasi A, Dunford J, Buccheri S, Caccamo N, Dieli F. Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a γδ-T lymphocytes-mediated activation mechanism. J Med Chem 2008;51:6800-6807.
190. Jahnke W, Rondeau J-M, Cotesta S, Marzinzik A, Pelle X, Geiser M, Strauss A, Gotte M, Bitsch F, Hemmig R, Henry C, Lehmann S, Glickman JF, Roddy TP, Stout SJ, Green JR. Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. Nat Chem Biol 2010;6:660-666.
191. Haudecoeur R, Peuchmaur M, Ahmed-Belkacem A, Pawlotsky J-M, Boumendjel A. Structure-activity relationships in the development of allosteric Hepatitis C virus RNA-dependent RNA polymerase inhibitors: Ten years of research. Med Res Rev 2013;33:934-984.
192. Chen KX, Njoroge FG. A review of HCV protease inhibitors. Curr Opin Investig Drugs 2009;10:821-837.
193. Saalau-Bethell SM, Woodhead AJ, Chessari G, Carr MG, Coyle J, Graham B, Hiscock SD, Murray CW, Pathuri P, Rich SJ, Richardson CJ, Williams PA, Jhoti H. Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat Chem Biol 2012;8:920-925.
194. Brandt P, Geitmann M, Danielson UH. Deconstruction of non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 for exploration of the optimization landscape of fragments. J Med Chem 2011;54:709-718.
195. Grant BJ, Lukman S, Hocker HJ, Sayyah J, Brown JH, McCammon JA, Gorfe AA. Novel allosteric sites on Ras for lead generation. PLoS ONE 2011;6:e25711.
196. Surade S, Ty N, Hengrung N, Lechartier B, Cole ST, Abell C, Blundell TL. A structure-guided fragment-based approach for the discovery of allosteric inhibitors targeting the lipophilic binding site of transcription factor EthR. Biochem J 2014;458:387-394.
197. Boehlein SK, Shaw JR, Stewart JD, Hannah LC. Heat stability and allosteric properties of the maize endosperm ADP-glucose pyrophosphorylase are intimately intertwined. Plant Physiol 2008;146:289-299.
198. Boehlein SK, Shaw JR, Hannah LC, Stewart JD. Probing allosteric binding sites of the maize endosperm ADP-glucose pyrophosphorylase. Plant Physiol 2010;152:85-95.
199. Hamouda AK, Jayakar SS, Chiara DC, Cohen JB. Photoaffinity labeling of nicotinic receptors: Diversity of drug binding sites. J Mol Neurosci 2013;doi:10.1007/s12031-013-0150-1.
200. Magnaghi P, D'Alessio R, Valsasina B, Avanzi N, Rizzi S, Asa D, Gasparri F, Cozzi L, Cucchi U, Orrenius C, Polucci P, Ballinari D, Perrera C, Leone A, Cervi G, Casale E, Xiao Y, Wong C, Anderson DJ, Galvani A, Donati D, O'Brien T, Jackson PK, Isacchi A. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol 2013;9:548-556.
201. Zhang J, Li C, Shi T, Chen K, Shen X, Jiang H. Lys169 of human glucokinase is a determinant for glucose phosphorylation: Implication for the atomic mechanism of glucokinase catalysis. PLoS One 2009;4:e6304.
202. Zhang J, Xu Y, Shen J, Luo X, Chen J, Chen K, Zhu W, Jiang H. Dynamic mechanism for the autophosphorylation of CheA histidine kinase: Molecular dynamics simulations. J Am Chem Soc 2005;127:11709-11719.
203. Wang F, Liu D, Wang H, Luo C, Zheng M, Liu H, Zhu W, Luo X, Zhang J, Jiang H. Computational screening for active compounds targeting protein sequences: Methodology and experimental validation. J Chem Inf Model. 2011;51:2821-2828.
204. 2L receptor: Evidence for the allosteric modulation of the dopamine receptor. Eur J Pharmacol 2010;641:96-101.
205. Li G-D, Chiara DC, Cohen JB, Olsen RW. Numerous classes of general anesthetics inhibit etomidate binding to γ-aminobutyric acid type A (GABAA) receptors. J Biol Chem 2010;285:8615-8620.
206. Pozdnyakov N, Murrey HE, Crump CJ, Pettersson M, Ballard TE, am Ende CW, Ahn K, Li Y-M, Bales KR, Johnson DS. γ-Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin. J Biol Chem 2013;288:9710-9720.
207. 3H]allyl m-trifluoromethyldiazirine mephobarbital, a photoreactive barbiturate. Mol Pharmacol 2014;85:735-746.
208. Huang W, Lu S, Huang Z, Liu X, Mou L, Luo Y, Zhao Y, Liu Y, Chen Z, Hou T, Zhang J. Allosite: A method for predicting allosteric sites. Bioinformatics 2013;29:2357-2359.
209. Dror RO, Green HF, Valant C, Borhani DW, Valcourt JR, Pan AC, Arlow DH, Canals M, Lane JR, Rahmani R, Baell JB, Sexton PM, Christopoulos A, Shaw DE. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature 2013;503:295-299.
210. Ramamoorthy D, Turos E, Guida WC. Identification of a new binding site in E. coli FabH using molecular dynamics simulations: Validation by computational alanine mutagenesis and docking studies. J Chem Inf Model 2013;53:1138-1156.
211. Qi Y, Wang Q, Tang B, Lai L. Identifying allosteric binding sites in proteins with a two-state Gō model for novel allosteric effector discovery. J Chem Theory Comput 2012;8:2962-2971.
212. Panjkovich A, Daura X. Exploiting protein flexibility to predict the location of allosteric sites. BMC Bioinform 2012;13:273.
213. Panjkovich A, Daura X. PARS: A web server for the prediction of protein allosteric and regulatory sites. Bioinformatics 2014;doi:10.1093/bioinformatics/btu002.
214. Mitternacht S, Berezovsky IN. Coherent conformational degrees of freedom as a structural basis for allosteric communication. PLoS Comput Biol 2011;7:e1002301.
215. Mitternacht S, Berezovsky IN. Binding leverage as a molecular basis for allosteric regulation. PLoS Comput Biol 2011;7:e1002148.
216. Goncearenco A, Mitternacht S, Yong T, Eisenhaber B, Eisenhaber F, Berezovsky IN. SPACER: Server for predicting allosteric communication and effects of regulation. Nucleic Acids Res 2013;41:W266-W272.